CORCEPT THERAPEUTICS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $761.4M | $675.0M | $482.4M | $401.9M | $366.0M |
| Cost of revenue | $13.0M | $10.9M | $6.5M | $5.4M | $5.3M |
| Selling, general & administrative | $448.7M | $280.3M | $184.3M | $152.8M | $122.4M |
| Research and development | $254.9M | $246.9M | $184.4M | $131.0M | $113.9M |
| Operating income | $44.8M | $137.0M | $107.3M | $112.6M | $124.5M |
| Pretax income | $66.5M | $161.5M | $124.6M | $116.2M | $125.0M |
| Income tax expense | -$33.2M | $20.3M | $18.4M | $14.8M | $12.5M |
| Net income | $99.7M | $141.2M | $106.1M | $101.4M | $112.5M |
| Balance Sheet | |||||
| Cash and equivalents | $120.5M | $127.7M | $135.6M | $66.3M | $77.6M |
| Current assets | $485.5M | $471.6M | $458.6M | $499.3M | $266.5M |
| Total assets | $836.7M | $840.6M | $621.5M | $583.4M | $423.8M |
| Current liabilities | $166.1M | $140.8M | $104.5M | $72.5M | $47.5M |
| Total liabilities | $188.8M | $161.0M | $114.8M | $81.6M | $48.0M |
| Stockholders' equity | $647.8M | $679.6M | $506.7M | $501.8M | $375.8M |
| Cash Flow Statement | |||||
| Cash from operations | $142.0M | $198.3M | $126.7M | $120.3M | $167.9M |
| Depreciation and amortization | $1.1M | $795,000 | $1.0M | $1.3M | $1.1M |
| Stock-based compensation | $84.5M | $61.4M | $48.9M | $42.4M | $42.9M |
| Capital expenditure | $211,000 | $2.2M | $139,000 | $413,000 | $469,000 |
| Free cash flow | $141.8M | $196.1M | $126.5M | $119.9M | $167.4M |
| Share repurchases | $172.9M | $15.7M | $0 | $0 | — |
Shares outstanding 107.4M · Free float 87.9%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.